Athenex Inc (NASDAQ:ATNX)’s share price was up 10.1% during mid-day trading on Tuesday . The stock traded as high as $16.03 and last traded at $15.87. Approximately 613,387 shares changed hands during trading, an increase of 255% from the average daily volume of 172,814 shares. The stock had previously closed at $14.41.

Several equities analysts have issued reports on the stock. Royal Bank of Canada assumed coverage on shares of Athenex in a report on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. Credit Suisse Group assumed coverage on shares of Athenex in a report on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Laidlaw assumed coverage on shares of Athenex in a report on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Finally, J P Morgan Chase & Co assumed coverage on shares of Athenex in a report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.64.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new position in Athenex in the third quarter worth $198,000. Schwab Charles Investment Management Inc. purchased a new position in Athenex in the third quarter worth $524,000. Bank of New York Mellon Corp grew its holdings in Athenex by 106.7% in the third quarter. Bank of New York Mellon Corp now owns 31,002 shares of the company’s stock worth $543,000 after purchasing an additional 16,002 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in Athenex in the third quarter worth $1,559,000. Finally, Goldman Sachs Group Inc. purchased a new position in Athenex in the second quarter worth $601,000. 2.93% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/12/athenex-atnx-trading-up-10-1.html.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.